Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Atara Biotherapeutics Inc
ATRA | US
6.68
USD1.51
29.21%
ATRA | US
Loading StockChartView...
About Atara Biotherapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
6.68
Open
5.66
High
7.30
Low
5.50
Atara Biotherapeutics Inc. develops therapies for patients with solid tumors hematologic cancers and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel) a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks California.
View LessATRA | US
Risk
143.0
Sharpe
-0.06
Luna's Score
58/100
Recommendation
Hold
Luna says (ATRA | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
179.9%1 month
143.0%3 months
170.6%6 months
134.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.97
Debt to equity
-0.81
Debt to assets
0.77
Ent. to EBITDA
-0.35
Ent. to rev.
1.13
PEG
-
Other Fundamentals
EBITDA
-162.12M
MarketCap
38.52M
MarketCap(USD)
38.52M
Div. yield
-
Op. margin
-62.41
Erngs. growth
-
Rev. growth
2.89K
Ret. on equity
-2.01K
Short ratio
2.32
Short perc.
9.40
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
3.38
Range1M
3.38
Range3M
15.22
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
9.94
Price X volume
21.32M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.35 | 0.53 | Cheaper |
| Ent. to Revenue | 1.13 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.97 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 170.58 | 72.80 | Riskier |
| Debt to Equity | -0.81 | -1.23 | Expensive |
| Debt to Assets | 0.77 | 0.25 | Expensive |
| Market Cap | 38.52M | 3.66B | Emerging |
